16.12

0.67% 0.1039

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$16.02

Offen:

$16.17

24-Stunden-Volumen:

381.51K

Relative Volume:

0.63

Marktkapitalisierung:

$830.07M

Einnahmen:

$107.46M

Nettoeinkommen (Verlust:

$105.90M

KGV:

7.9522

EPS:

2.0276

Netto-Cashflow:

$238.50M

1W Leistung:

+5.69%

1M Leistung:

+18.85%

6M Leistung:

+10.62%

1J Leistung:

+91.09%

1-Tages-Spanne:

$16.02

$16.50

1-Wochen-Bereich:

$15.38

$16.50

52-Wochen-Spanne:

$7.90

$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-03-25

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	16.12	824.92M	107.46M	105.90M	238.50M	2.0276
VRTX Vertex Pharmaceuticals Inc	433.56	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.84	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.14	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.59	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.86	35.01B	606.42M	-1.28B	-997.58M	-6.403

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-05	Herabstufung	Oppenheimer	Outperform → Perform
2026-03-04	Herabstufung	B. Riley Securities	Buy → Neutral
2025-12-03	Eingeleitet	Oppenheimer	Outperform
2025-09-12	Eingeleitet	B. Riley Securities	Buy
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

12:49 PM

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research

12:49 PM

12:46 PM

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

12:46 PM

01:34 AM

Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat

01:34 AM

Apr 05, 2026

JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH - MarketBeat

Apr 05, 2026

Apr 03, 2026

Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares - Stock Titan

Apr 03, 2026

Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4 - Stock Titan

Apr 03, 2026

Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant - Stock Titan

Apr 03, 2026

Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing - Stock Titan

Apr 03, 2026

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com

Apr 03, 2026

Apr 02, 2026

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Apr 02, 2026

TBPH PE Ratio & Valuation, Is TBPH Overvalued - Intellectia AI

Apr 02, 2026

Apr 01, 2026

How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Apr 01, 2026

Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat

Apr 01, 2026

Mar 31, 2026

Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo

Mar 31, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 31, 2026

Mar 30, 2026

Big Picture: Can Theravance Biopharma Inc sustain its profitabilityLayoff News & Daily Profit Focused Screening - baoquankhu1.vn

Mar 30, 2026

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement - tipranks.com

Mar 30, 2026